3/3/2009

Erbitux makers Eli Lilly and Co. and Bristol-Myers Squibb announced that the FDA postponed its approval decision on the drug's use to treat head and neck tumors. The application is separate from the companies' recently withdrawn request to promote Erbitux for nonsmall-cell lung cancer.

Related Summaries